



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



PRODUCT INFORMATION



JMJD2A (human, recombinant; His-tagged)


Item No. 10336

Overview and Properties

| | |
|-------------------|---|
| Synonyms: | JHDM3A, Jumonji Domain Containing 2A, KDM4A, Lysine (K)-specific Demethylase 4A |
| Source: | Recombinant N-terminal His-tagged protein expressed in <i>E. coli</i> |
| Amino Acids: | 1-350 (C-terminal truncation) |
| Uniprot No.: | O75164 |
| Molecular Weight: | 43.0 kDa |
| Storage: | -80°C (as supplied) |
| Stability: | ≥6 months; avoid freeze/thaw cycles by aliquoting protein |
| Purity: | ≥95% estimated by SDS-PAGE |
| Supplied in: | 50 mM HEPES, pH 7.4, containing 150 mM sodium chloride and 20% glycerol |
| Protein | |
| Concentration: | batch specific |

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Image



Lane 1: MW Markers
Lane 2: JMJD2A (1 µg)
Lane 3: JMJD2A (2 µg)
Lane 4: JMJD2A (4 µg)

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/31/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 - USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION

Description

Jumonji Domain Containing 2A (JMJD2A) is a lysine-specific demethylase that catalyzes the demethylation of histone H3 at lysine residues 9 and 36 and histone H1.4 at lysine residue 26.¹⁻³ It is composed of the JmjN N-terminal domain, JmjC catalytic domain, two plant homeodomains (PHDs), and two tudor domains that recognize the methylated histones.³ JMJD2A is ubiquitously expressed and localized to the nucleus.⁴ It is involved in the regulation of gene expression in a context-dependent manner, having roles in both transcriptional silencing and activation of androgen and estrogen receptors (ERs).³ Knockdown of JMJD2A inhibits the proliferation of ER-positive and -negative breast cancer cells and induces apoptosis and cell cycle arrest in colon cancer cells. It is overexpressed in various cancers, including prostate, lung, and colorectal, as well as glioblastomas and endometrial carcinomas, and is associated with higher tumor grade and decreased disease-free survival in breast cancer.⁵ Cayman's JMJD2A (human, recombinant) can be used for ELISA and Western blot (WB) applications.

References

1. Couture, J.F., Collazo, E., Ortiz-Tello, P.A., et al. Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone demethylase. *Nat. Struct. Mol. Biol.* **14**(8), 689-695 (2007).
2. Lee, J., Thompson, J.R., Botuyan, M.V., et al. Distinct binding modes specify the recognition of methylated histones H3K4 and H4K20 by JMJD2A-tudor. *Nat. Struct. Mol. Biol.* **15**(1), 109-111 (2008).
3. Berry, W.L. and Janknecht, R. KDM4/JMJD2 histone demethylases: Epigenetic regulators in cancer cells. *Cancer Res.* **73**(10), 2936-2942 (2013).
4. Gray, S.G., Iglesias, A.H., Lizcano, F., et al. Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein. *J. Biol. Chem.* **280**(31), 28507-28518 (2005).
5. Lee, D.H., Kim, G.W., Jeon, Y.H., et al. Advances in histone demethylase KDM4 as cancer therapeutic targets. *FASEB J.* **34**(3), 3461-3484 (2020).